Study of STYLAGE® XXL for Volume Deficiency in the Mid-Face

NCT ID: NCT05355454

Last Updated: 2025-09-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 90 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-06-06
• Study Completion Date: 2025-04-25

Brief Summary

The primary objective of the study is to demonstrate the superiority of STYLAGE® XXL versus no treatment at 24 weeks after baseline for the creation or restoration of volume deficit in the mid-face.

Detailed Description

This is a multicenter, prospective, randomized, no-treatment controlled post-market clinical follow-up of a class III medical device. This study is designed to evaluate the safety and effectiveness of STYLAGE® XXL in the restorationor creation of volume in the mid-face.

The objective of this study is to demonstrate the superiority of STYLAGE® XXL versus no treatment at 24 weeks after baseline for the creation or restoration of volume deficit in the mid-face.

Assessment of superiority will be based on 3D analysis of the volumetric change, using a validated imaging system.

Effectiveness of STYLAGE® XXL will be demonstrated if the mean volumetric change at 24 weeks after baseline from pre-treatment in the treatment group is statistically superior to the mean change in the delayed treatment (control) group.

In total, approximately 90 subjects will be enrolled across three study centers in Switzerland, Austria, and France.

Subjects will be randomized to the treatment group or delayed treatment (control) group at a 5:1 ratio (i.e., there will be 5 more subjects treated with STYLAGE® XXL at baseline as compared to subjects who will be in the no-treatment (control) group and who will receive a delayed treatment with STYLAGE® XXL at 24 weeks after baseline).

The total duration of subject participation ranges from 18-19 months (treatment group) to 24-25 months (delayed treatment (control) group). Overall study duration including the enrolment period is expected to take approximately 30-31 months.

Conditions

Volume Deficiency in the Mid-Face; Aging; Aesthetics

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

STYLAGE® XXL Treatment Group

Subjects randomized (5:1 ratio) to receive an initial treatment with STYLAGE® XXL Crosslinked Hyaluronic Acid Gel up to 8mL, based on the PI's assessment, in combination with the aesthetic goal of the subject, then an optional touch-up treatment session 4 weeks later, up to 4mL.

Subjects will also be offered an optional retreatment at week 72 after initial treatment, up to 8mL.

Group Type: EXPERIMENTAL

STYLAGE® XXL

Intervention Type: DEVICE

Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek at the first session, on each side of the face.

Up to 1.0 mL in the zygomaticomalar region and optionally up to 1.0 mL in the anteromedial cheek for the optional touch-up session, on each side of the face.

Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek before study exit, on each side of the face.

No-Treatment Control Group, then Delayed Treatment with STYLAGE® XXL

No-Treatment for the first 6-month, then subjects will receive a delayed treatment with STYLAGE® XXL Crosslinked Hyaluronic Acid Gel up to 8mL, based on the PI's assessment, in combination with the aesthetic goal of the subject, then an optional touch-up treatment session 4 weeks later, up to 4mL.

Subjects will also be offered an optional retreatment at week 72 after initial treatment, up to 8mL.

Group Type: OTHER

STYLAGE® XXL

Intervention Type: DEVICE

Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek at the first session, on each side of the face.

Up to 1.0 mL in the zygomaticomalar region and optionally up to 1.0 mL in the anteromedial cheek for the optional touch-up session, on each side of the face.

Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek before study exit, on each side of the face.

Interventions

STYLAGE® XXL

Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek at the first session, on each side of the face.

Up to 1.0 mL in the zygomaticomalar region and optionally up to 1.0 mL in the anteromedial cheek for the optional touch-up session, on each side of the face.

Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek before study exit, on each side of the face.

Intervention Type: DEVICE

STYLAGE® XXL

Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek at the first session, on each side of the face.

Up to 1.0 mL in the zygomaticomalar region and optionally up to 1.0 mL in the anteromedial cheek for the optional touch-up session, on each side of the face.

Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek before study exit, on each side of the face.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Aged between 30 and 65 years
• Seeking correction of his/her mid-face volume deficit, and agrees with recommendation by the Investigator
• Accept the obligation not to receive any other facial procedures or treatments impacting facial volume augmentation at any time during the study
• Able to follow study instructions and likely to complete all required visits, as assessed by the Investigator
• Psychologically able to understand the study related information and to give a written informed consent
• Have voluntarily provided written informed consent to participate in the study, and use of data privacy (sign the ethics committee approved Informed Consent Form), prior to any study-related procedure being performed
• Female of childbearing potential (sexually active, not sterile, nor postmenopausal for at least 1 year) must have a negative urine pregnancy test (UPT) at Visit 1 (or Visit 1b), and use a medically accepted contraceptive regimen since at least 12 weeks before the beginning of the study and for the duration of the study
• Affiliated to a health social security system (for France only)

Exclusion Criteria

In terms of population:

• Pregnant or breastfeeding woman, or planning a pregnancy during the study
• Scars, moles, tattoo, or anything on the face which might interfere with the evaluation
• Subject who had been deprived of their freedom by administrative or legal decision or who is under guardianship
• Subject in a social or sanitary establishment
• Subject participating to another research on human beings or who is in an exclusion period of one
• Subject having received 4500 euros indemnities for participation in researches involving human beings in the 12 previous months, including participation in the present study (for France only)

In terms of associated pathology:

• Subject presenting any symptom which can be related to a medical condition that is likely to make the subject not being compliant with the study schedule, at the discretion of the investigator
• Subject suffering from a severe or progressive disease or any other pathology that may interfere with the evaluation of the study results
• Subject with known history of or suffering from autoimmune disease and/or immune deficiency
• Subject suffering from active inflammatory and/or infectious cutaneous disorders in or near the studied zones (e.g. herpes, acne). Subject with recurrent herpes in the Midface area is not eligible even if asymptomatic at time of inclusion
• Subject prone to develop inflammatory skin conditions or having tendency to bleeding disorders
• Subject having history of allergy or anaphylactic shock including hypersensitivity to hyaluronic acid or to one of the components of the tested device
• Subject with a history of streptococcal disease, such as acute rheumatic fever or recurrent sore throats with cardiac localisation
• Subject with a tendency to develop keloids or hypertrophic scars

Relating to previous or ongoing treatment:

• Subject having received treatment with a laser, a dermabrasion, a surgery, a peeling, or other ablative procedure on the Midface area within the past 12 months prior to inclusion
• Subject having received injection with a resorbable filling product in the Midface area within the past 18 months prior to inclusion
• Subject having received at any time injection with a slowly resorbable filling product (e.g. polylactic acid, calcium hydroxyapatite, combinations of HA and Hypromellose) or with a non-resorbable filling product (e.g. polyacrylamide or silicone)
• Subject having received at any time a treatment with tensor threads in the Midface area
• Subject under medications which may cause lipo-atrophy
• Subject using medication such as aspirin, NSAIDs (e.g. ibuprofen), antiplatelet agents, anticoagulants, vitamin C within one week prior to inclusion and not agreeing not to take such treatments within 1 week prior to visit 2 (M1) or being a chronic user of anticoagulant treatment
• Subject undergoing a topical treatment on the test area or a systemic treatment:
• Antihistamines during the 2 weeks prior to study start
• Immunosuppressors and/or corticoids during the 4 weeks prior to study start
• Retinoids during the 6 months prior to study start

• Minimum Eligible Age: 30 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Avania B.V.

UNKNOWN

Sponsor Role: collaborator

Canfield Scientific Inc.

UNKNOWN

Sponsor Role: collaborator

Laboratoires Vivacy

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Hervé RASPALDO, MD

Role: PRINCIPAL_INVESTIGATOR

Private Clinic, GENEVA, SWITZERLAND

Hugues CARTIER, MD

Role: PRINCIPAL_INVESTIGATOR

Centre Medical Saint-Jean, ARRAS, FRANCE

Thomas RAPPL, MD

Role: PRINCIPAL_INVESTIGATOR

Medical Aesthetic Research Academy, GRAZ, AUSTRIA

Cyril CLERICO, MD

Role: PRINCIPAL_INVESTIGATOR

Private Practice, NICE, FRANCE

Locations

Centre Medical Saint Jean

Arras, , France

Countries

France

Other Identifiers

VIV-STYL-XXL-02

Identifier Type: -

Identifier Source: org_study_id